title: [Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].
abstract: In the context of a need for improved strategies to control glycemia in patients with type 2 diabetes, new information was discussed during the American Diabetes Association's annual meeting on the dipeptidyl peptidase 4 inhibitor sitagliptin. As reviewed below, clinical trials corroborated the feasibility of adding sitagliptin to ongoing metformin or pioglitazone therapy, without the risk for hypoglycemia or the negative impact on body weight observed after add-on sulfonylureas, although the neutral or beneficial effect of sitagliptin on body weight resulted from a complex interaction with baseline levels of hemoglobin A1c levels and the change brought about by treatment. New studies of sitagliptin presented during the meeting also indicated additional effects of the drug not mediated by inhibition of dipeptidyl peptidase-4, but through direct inhibition of endogenous glucose production and/or glucagon responses and improved β-cell glucose sensitivity.
authors.affiliation: Thomson Reuters, Barcelona, Spain.
authors.forename: X
authors.initials: X
authors.lastname: Rabasseda
mesh_terms: D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D014230:Triazoles